ARS Pharmaceuticals, Inc. SPRY Proceeds from exercises of stock options and other stock issuances
Proceeds from exercises of stock options and other stock issuances at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s proceeds from exercises of stock options and other stock issuances.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s proceeds from exercises of stock options and other stock issuances?
- ARS Pharmaceuticals, Inc. (SPRY) reported proceeds from exercises of stock options and other stock issuances of $62K in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s proceeds from exercises of stock options and other stock issuances changed year-over-year?
- ARS Pharmaceuticals, Inc.'s proceeds from exercises of stock options and other stock issuances decreased by 91.4% year-over-year, from $725K to $62K.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s proceeds from exercises of stock options and other stock issuances?
- Over 3 years (2022 to 2025), ARS Pharmaceuticals, Inc.'s proceeds from exercises of stock options and other stock issuances has grown at a 115.2% compound annual growth rate (CAGR), from $570K to $5.68M.